Key takeaways
Saxagliptin (Onglyza) and insulin lispro (Humalog) are both medications used to manage diabetes, but they have some important differences. Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor taken once daily by mouth, while insulin lispro is a fast-acting insulin injected under the skin multiple times a day, typically before meals. Saxagliptin is available in generic form, whereas insulin lispro is available as a lower-cost generic and under several brand names, including Humalog and Humalog Kwikpen. Common side effects of saxagliptin include headaches and infections, while insulin lispro can cause low blood sugar and weight gain. Saxagliptin has a low risk of causing hypoglycemia when used alone, but insulin lispro can lead to low blood sugar, especially if not taken with food. Additionally, saxagliptin may increase the risk of heart failure in some people.
